Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria-Reference-Cited by-同舟云学术

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria

Published:2021-11-17 Issue: Volume: Page:
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Goulooze Sebastiaan Camiel,Snelder Nelleke,Seelmann Andreas,Horvat-Broecker Andrea,Brinker Meike,Joseph Amer,Garmann Dirk,Lippert Joerg,Eissing Thomas^ORCID

Funder

Bayer

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-021-01083-1.pdf

Reference21 articles.

1. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.

2. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333–44.

3. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021.

4. Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Dev Res. 2021;82(3):341–63.

5. Capelli I, Gasperoni L, Ruggeri M, Donati G, Baraldi O, Sorrenti G, et al. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol. 2020;33(1):37–48.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-21

2. Finerenone and diabetic renal disease: a narrative review;Endocrine;2024-08-14

3. Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease;Pharmaceuticals;2024-03-26

4. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review;Postgraduate Medicine;2024-02-16

5. Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases;Frontiers in Endocrinology;2023-12-20